@FierceMedDev: Sony and Samsung are revving up their medtech rivalry. More | Follow @FierceMedDev
@MarkHFierce: Dx investment continues, this time at Charles River Laboratories. Release | Follow @MarkHFierce
@DamianFierce: The FDA wants feedback on its four-point plan to improve post-market surveillance for medical devices. Story | Follow @DamianFierce
> Stryker ($SYK) told investors that it has ceded market share in Europe and plans to refocus its efforts to better perform there. News
> As the medical device tax looms, KPMG surveyed execs in the industry, reporting that 55% are expecting to have trouble complying with the tax and 40% are considering cutting costs or raising prices to pay it. Article
> Innovative Trauma Care, a Canadian developer of wound care devices, is opening its U.S. headquarters in San Antonio. Item
> Accuray ($ARAY), a developer of radiation oncology medical devices, generated just over $100 million in net revenue during its fiscal 2012 fourth quarter, a decline over last year's combined revenue of Accuray and the now-acquired TomoTherapy. Release
> Medtronic ($MDT) CEO Omar Ishrak is among life sciences executives who have become avid tweeters. Story
> Medical devicemaker LDR Holding gained FDA clearance to market its Avenue L lateral lumber cage spinal device. Story
Biotech News
@FierceBiotech: Respiratory virus tried as targeted cancer treatment. Story | Follow @FierceBiotech
@JohnCFierce: Want to fix healthcare costs? IOM says there's $750B a year squandered in the U.S. Report | Follow @JohnCFierce
> Talent hunt spurs Sarepta's cross-country move to booming Boston hub. Story
> Safety threat forces AstraZeneca to scuttle obesity program. Report
> Promising PhIII apremilast data clear Celgene's path to the FDA. Article
> Pfizer partners on lung cancer drug in deal to speed Asian development. News
Pharma News
@FiercePharma: GSK's Benlysta gets another shot at U.K. market. Story | Follow @FiercePharma
> Drug shortages ease but remain serious problem. Story
> J&J, Bayer try to answer FDA concerns on Xarelto. Report
> Loss of Makena suit against FDA compounds KV's problems. Article